Evidence map›Paper›PMID 35467256›Full record

ArticleMolecular biotechnology2023

Expression, Purification, Structural and Functional Characterization of Recombinant Human Parvulin 17.

Alessandra Monti, Raffaele Ronca, Giuseppe Campiani, Menotti Ruvo, Nunzianna Doti

Open access · hybridAbstract read
In one paragraph

Article in Molecular biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Alessandra MontiInstituto di Biostrutture e Bioimmagini-CNR, Via Pietro Castellino 111, 80131, Napoli, Italy.
Raffaele RoncaInstituto di Biostrutture e Bioimmagini-CNR, Via Pietro Castellino 111, 80131, Napoli, Italy.
Giuseppe CampianiDipartimento di Biotecnologie, Chimica e Farmacia, Via Aldo Moro, 2, 53100, Siena, Italy.
Menotti RuvoInstituto di Biostrutture e Bioimmagini-CNR, Via Pietro Castellino 111, 80131, Napoli, Italy.
Nunzianna DotiInstituto di Biostrutture e Bioimmagini-CNR, Via Pietro Castellino 111, 80131, Napoli, Italy. nunzianna.doti@cnr.it.ORCID http://orcid.org/0000-0003-2952-6658
Institute of Biostructure and Bioimaging · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parvulins, peptidyl-prolyl isomerase enzymes (PPIase), catalyze the cis-trans isomerization of prolyl bonds in polypeptides, contributing to folding and function regulation of many proteins. Among Parvulins, Par17, exclusively expressed in hominids, is the least examined in terms of structure, catalytic function and cellular activity. Setting the conditions for the preparation of recombinant active Par17 may therefore significantly foster future studies. Here, we comparatively evaluated the impact of several parameters, including host strains, culture media, isopropyl ß-D-1-thiogalactopyranoside concentration, post-induction incubation time and temperature, on the overexpression of Par17 in E. coli cells. A similar approach was also comparatively adopted for the preparation of the recombinant full-length Pin1 protein, the most representative Parvulin, and the catalytic domains of both enzymes. Proteins were efficiently expressed and purified to homogeneity and were subjected to a structural characterization by Size Exclusion Chromatography and Circular Dichroism. Moreover, a single-step homogeneous protease-based fluorimetric assay, potentially scalable in HTS format, has been developed for determining the peptidyl-prolyl cis-trans isomerase activity of recombinant Parvulins. Results obtained show that proteins are folded and active. These new data mark an important milestone for progressing the investigation of Parvulins.

Indexed as

Escherichia coliPeptidyl-Prolyl Cis-Trans Isomerase NIMA-Interacting 4HumansNIMA-Interacting Peptidylprolyl IsomerasePeptidesPeptidylprolyl IsomeraseRecombinant ProteinsNIMA-Interacting Peptidylprolyl IsomerasePeptidesPeptidyl-Prolyl Cis-Trans Isomerase NIMA-Interacting 4Peptidylprolyl IsomerasePIN1 protein, humanRecombinant ProteinsCircular Dichroism spectroscopyFRET-based peptidyl-prolyl cis–trans isomerase assayHigh Throughput Screening (HTS)Par17ParvulinsPin1Size-Exclusion Chromatography

Identifiers

PMID35467256
PMCPMC9935730
OpenAlexW4224314211

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.